When: Price above $435 without material 200 SMA extension compression

Then: No add; preserve capital, do not chase

HOLD defensively with trim recommendations; do not add at $433.73; wait for Tier 1 zone at $400-415

• RSI rolled over from 79.80 to 71.53 in single session indicating momentum exhaustion signature
• ATR expanded 46% since May, signaling volatility expansion that historically precedes chop
• Upper Bollinger Band at $443.98 actively rejected price at $443.20
• MACD histogram at +2.13 expanded from near +0.5, measuring burned fuel not remaining momentum
• AMGN trading 24% above 200-day moving average at upper band — entry is poor, not the stock
• Traders own analysis shows 3.8% upside vs 6.6% downside — 1-to-2 risk-reward in favor of bears
• Gross margin compressing 840 basis points from 75.7% (2022) to 67.3% (2025)
• 57% FCF payout ratio with zero buybacks in 2025 and $45.5 billion net debt remaining
• No retail confirmation — institutional-only rally is thinner and unwinds faster
• Recommend trimming 20-25% into this rally to lock gains and reduce exposure
• Position sizing should tighten to 1-1.5% portfolio risk maximum (vs current 2-3%) given ATR at $10.97 at upper band
• Stop at $399 creates whipsaw risk given middle Bollinger band at $404.99 and 50 SMA at $376.93

→ vs aggressive: Asymmetric upside claim is false — traders own analysis shows 3.8% upside vs 6.6% downside, a negative skew not asymmetric upside. 24% above 200-day MA is not a place for capital preservation or opportunistic entry.

→ vs aggressive: 37% DCF fair value gap is single model output with unaudited assumptions — not a floor. 2022 biotech cohort had similar DCF gaps before multiples compressed.

→ vs aggressive: Asking 'what else are you going to buy' is intellectually lazy — job of risk analyst is to find what not to pay up for, not find best alternative.

→ vs neutral: Stop at $399 will get whipsawed — middle Bollinger band at $404.99 is healthy mean reversion target that would fire the stop before stock bounces from 50 SMA at $376.93.

→ vs neutral: 2-3% portfolio risk per position is too generous — should be 1-1.5% maximum given ATR at $10.97 and stock at upper band. Entry quality should drive sizing, not story quality.

HOLD; size at 1.5-2% portfolio risk (not 2-3% or 1-1.5%); stop at $399 or trailing stop below 10 EMA at $420.94 on two consecutive daily closes; add only in $400-$415 (Tier 1) or $385-$395 (Tier 2) zones, never above $420; trim only on simultaneous MACD negativity, RSI bearish divergence, and close below 10 EMA; maintain defensive allocation

• Aggressive analyst correct that structural case is strong: 17 products at $1B+ annually, $8-10B FCF, $10B deleveraging, 0.41 beta, 17.8x forward P/E vs 50%+ EPS growth
• Conservative analyst correct that entry is poor: RSI overbought at 71.53 (cooled from 79.80), price 24% above 200-day moving average, upper Bollinger band rejected, ATR expanded 46% since May
• Position sizing: split the difference at 1.5-2% of portfolio—fundamentals justify more than 1% but entry quality does not justify 2-3%
• Stop strategy: hard stop at $399 with trailing alternative based on 10 EMA at $420.94; exit if price closes below 10 EMA for two consecutive daily sessions
• Add discipline: Tier 1 zone $400-$415, Tier 2 zone $385-$395; no adds above $420; missing a move you shouldn't have taken is not a mistake
• Trim triggers (three conditions must align): MACD histogram turns negative AND RSI makes bearish divergence (lower high) AND price closes below 10 EMA at $420.94
• Macro overlay: 86% probability of zero Fed cuts and 8% recession probability are bullish for relative defensives, but rising yields are a headwind for absolute multiples; trailing P/E of 26.9x is not cheap
• Gross margin compression from 75.7% to 67.3% is offset by 89% YoY net income rebound in 2025; operating leverage story intact despite static margin snapshot
• Thin retail participation is a feature of the investor base, not a weakness signal; institutional bid is real for $234B large-cap with 2.28% dividend yield
• Reassess at next earnings print or on clean breakout above $444 or breakdown below $405

→ vs aggressive: DCF 37% fair value gap depends entirely on terminal growth assumptions, discount rates, and pipeline success probabilities that cannot be audited; anchoring on a spreadsheet is not the same as trading the market

→ vs aggressive: ATR expanded 46% since May—volatility expansion precedes chop in both directions, not just continuation; treating the trend as permanent and mean reversion as optional is confirmation bias

→ vs aggressive: 52-week range spans $269.77 to $443.20, a 64% intra-year swing in a name with 0.41 beta; wider bands are not inherently bullish

→ vs aggressive: 'What else would you buy' framing is intellectually dishonest—cash and shorter-duration instruments are positions; the job is to deploy capital where entry compensates for risk

→ vs conservative: Trim recommendation is premature—MACD histogram still expanding at +2.13, 10 EMA slope steepening, no confirmed momentum breakdown; selling into a coil risks missing the next leg

→ vs conservative: Thin retail confirmation is overweighted—AMGN is a $234B large-cap defensive compounder where institutional ownership is the relevant signal, not Reddit activity

→ vs conservative: Gross margin compression from 75.7% to 67.3% paired with 89% YoY net income rebound shows operating leverage is working—the static margin snapshot is misleading

→ vs conservative: 1-1.5% position sizing implies near-cash posture and gives up asymmetric quality over multi-quarter horizon; you cannot simultaneously believe fundamentals are durable and go to minimum sizing